Illustrative Cases and Summary. A 50 year old European woman who is new to your practice comes to see you late on Friday afternoon with a sore throat.

Slides:



Advertisements
Similar presentations
Hypertension NPN 200 Medical Surgical I. Description of Hypertension Intermittent or sustained elevation in the diastolic or systolic blood pressure:
Advertisements

Treatment in Cardiac disease The PNs Roll Dr. Sergio Diez Alvarez Staff Specialist Physician Armidale Hospital.
Cardio-Metabolic Syndrome Guidelines on Education, Detection and Early Treatment  Heval Mohamed Kelli, PGY-2 Emory Internal Medicine Residency no conflict.
U.S. Dept of Health and Human Services. National High Blood Pressure Education Program. Seventh Report of Joint National Committee on Prevention, Detection,
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
CKD In Primary Care Dr Mohammed Javid.
Updated December 2005 PREVENT DIABETES AND HEART DISEASE Enjoy a healthy lifestyle and improve your health 1.
CVD prevention & management: a new approach for primary care Rod Jackson School of Population Health University of Auckland New Zealand.
Cholesterol and Lipids TIPS Wokefield Park 15/5/2013.
ADVICE. Advice Strongly advise adherence to diet and medication Smoking cessation, exercise, weight reduction Ensure diabetes education and advise Diabetes.
BHS Guidelines for the management of hypertension BHS IV, 2004 and Update of the NICE Hypertension Guideline, 2006 Guidelines for management of hypertension:
Heart Disease Map.
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Health Screening. Should you go for health screening? Health screening helps to discover if a person is suffering from a particular disease or condition,
FATS4 Linking cases to the guideline Jane S Skinner Consultant Community Cardiologist.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Source: Site Name and Year IHS Diabetes Audit Diabetes Health Status Report ______Site Name_________ Health Outcomes and Care Given to Patients with Diabetes.
1 The JNC 7 recommendations for initial or combination drug therapy are based on sound scientific evidence.
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Results of Monotherapy in ALLHAT: On-treatment Analyses ALLHAT Outcomes for participants who received no step-up drugs.
Rapid E clinical guidance in the management of Type 2 diabetes New Zealand Guidelines Group.
CVD preventive interventions WORKSHOP Jurate Klumbiene Kaunas University of Medicine, Kaunas, Lithuania.
METABOLIC Syndrome: a Global Perspective
1 Presenter Disclosure Information FINANCIAL DISCLOSURE: DSMB’s: Merck, Takeda Barry R. Davis, MD, PhD Clinical Outcomes in Participants with Dysmetabolic.
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial ALLHAT study overview Double-blind, randomized trial to determine whether.
Low level of high density lipoprotein cholesterol in children of patients with premature coronary heart disease. Relation to own and parental characteristics.
Hypertension in patients with Type 2 Diabetes Mellitus – why are we failing to meet the targets? Walter van der Merwe Renal Physician, North Shore Hospital.
NYU Medical Grand Rounds Clinical Vignette Krista Michelin MD, PGY-3 March 17, 2010 U NITED S TATES D EPARTMENT OF V ETERANS A FFAIRS.
0902CZR01NL537SS0901 RENAAL Altering the Course of Renal Disease in Hypertensive Patients with Type 2 Diabetes and Nephropathy with the A II Antagonist.
Achieving Blood Pressure Targets Setting Expectations to Achieve Blood Pressure Control – Applying a Business Principle to Hypertension Management.
0CTOBER 2010 An Approach for Sub-Saharan Africa. Dr. Linda Hawker, MD, CCFP General Practice Kelowna BC Canada.
1 Hypertension Overview. 2 Leading Risks For Death (World Health Organization 2002) Cholesterol Alcohol HYPERTENSION Tobacco use Overweight.
Rationale, Study Design & Study Population
CARDIOVASCULAR CARE of the OUTPATIENT Diane M. Enzweiler, MSN, ANP-BC St. Elizabeth Physicians: Heart and Vascular.
NICE GUIDELINES HYPERTENSION Masroor Syed. Latest Issue June 2006 Evidence Based uickrefguide.pdf
Avoiding Cardiovascular Events through COMbination Therapy in Patients LIving with Systolic Hypertension The First Outcomes Trial of Initial Therapy With.
Dyslipidemia.  Dyslipidemia is elevation of plasma cholesterol, triglycerides (TGs), or both, or a low high- density lipoprotein level that contributes.
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
Hypertension Dr Nidhi Bhargava 8/10/13. Why Treat Increased risk of cardiovascular death and mortality Increased systolic, diastolic and pulse pressures.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Clinical Correlations The NYU Langone Online Journal of Medicine
SPARCL Stroke Prevention by Aggressive Reduction in Cholesterol Levels trial.
Group work 5 Hypertension case discussions. Objectives At the end of this session, the trainees should: Be able to explain steps of correct BP measurement.
Clinical Practice Glycemic Management of Type 2 Diabetes Mellitus Faramarz Ismail-Beigi, M.D., Ph.D. Dr.kalantar N Engl J Med Volume 366(14):
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
7/27/2006 Outcomes in Hypertensive Black and Nonblack Patients Treated with Chlorthalidone, Amlodipine, and Lisinopril* * Wright JT, Dunn JK, Cutler JA.
Hypertension Family Medicine Specialist CME October 15-17, 2012 Pakse.
ALLHAT 6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (3 GROUPS by GFR)
Case I A 47 old male presents to your office for a yearly checkup. He smokes 40 cigarette/day, and examination detect wheezy chest and bronchospasm. His.
6/5/ CARDIOVASCULAR DISEASE OUTCOMES IN HYPERTENSIVE PATIENTS STRATIFIED BY BASELINE GLOMERULAR FILTRATION RATE (4 GROUPS by GFR) ALLHAT.
Laboratory Testing For Cardiovascular Risk
Insulin Optimisation Workshop Theingi Aung & Claire Rowell.
April 22, 2016 Connie Tien Daniel Kim Jeffrey Hughes Michelle Di Fiore
Results from ASCOT-BPLA: Anglo-Scandinavian Cardiac Outcomes Trial–Blood Pressure Lowering Arm VBWG.
Presented by Slyter Nutrition Consulting Services.
Dr John Cox Diabetes in Primary Care Conference Cork
Nephrology Journal Club The SPRINT Trial Parker Gregg
The Anglo Scandinavian Cardiac Outcomes Trial
ASSOCIATIONS OF METABOLIC SYNDROME COMPONENTS WITH CRITERIA FOR THE CLINICAL DIAGNOSIS OF THE METABOLIC SYNDROME AS PROPOSED BY THE NCEP-ATP III Metabolic.
HTN Cases Pharmacotherapy - 1.
Diabetes Health Status Report
The Hypertension in the Very Elderly Trial (HYVET)
Post-Heart Failure Mortality
Goals & Guidelines A summary of international guidelines for CHD
Train-the-Trainer Cases
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
An ACCORD BP sub-analysis HR: 1.06; 95%CI: ; P=0.61
Train-the-Trainer Cases
Train-the-Trainer Cases
Presentation transcript:

Illustrative Cases and Summary

A 50 year old European woman who is new to your practice comes to see you late on Friday afternoon with a sore throat which is probably viral. She has a past history of hypertension, but is not on antihypertensives currently. You take her blood pressure and it is 230/130. After 15 minutes quiet rest your nurse remeasures the blood pressure at 210/110. How should she be managed from here?

Hypertensive Urgency or Emergency? Hypertensive Emergency Very high BP with evidence of rapidly progressive target organ damage retinopathy heart failure rapidly progressive renal impairment neurological -TIA/ stroke/ reduced level of consciousness Medical emergency – requiring hospital admission

Hypertensive Urgency Very high BP without evidence of rapidly progressive target organ damage Does not require urgent hospital admission, but does require careful management, close supervision, and review within 1-3 days

This patient needs:- careful physical examination including fundoscopy 12-lead ECG urine Dipstick And send off FBC urea creatinine, electrolytes urine microscopy and spot urine albumin/creatinine ratio

Assuming no evidence of “hypertensive emergency”, start on medication and see again on Monday Start on 2 drugs, either ACE-inhibitor/ thiazide or ACE- inhibitor/CCB eg lisinopril 10mg/ chlorthalidone 12.5mg stat and daily until reviewed or lisinopril 10mg/ amlodipine 5mg stat and daily until reviewed

You see her again on Monday afternoon:- Lab tests have come back normal She feels OK Resting BP 170/100 (on lisinopril 10mg and amlodipine 5mg) Where to from here?

Leave on same meds and review in 2 weeks ↓ BP 160/95 ↓ Increase lisinopril to 20mg and review in 2 weeks ↓ BP 155/92 ↓ Increase amlodipine to 10mg and review in 2 weeks ↓ BP 148/90 ↓ Add chlorthlalidone 12.5mg and review in 2 weeks ↓ BP 143/88 ↓ Increase chlorthalidone to 25mg and review in 2 weeks ↓ BP 137/85 (at target)

You take over the care of a 37 year old Indian man. He has a bad family history of diabetes and premature cardiovascular disease. His father (who was not known to be diabetic) died at 43 of an apparent heart attack. You are only seeing him because his wife forces him to come in for a checkup because she is worried about his family history. He is a non-smoker and currently on no medication Examination BMI 27, abdominal girth 95cm, BP 134/90 Investigations Fasting glucose 5.6mmol/l, cholesterol 4.4mmol/l HDL 0.8mmol/l LDL 3.0mmo/l triglyceride 2.2mmol/l creatinine 75umol/l spot urine albumin-creatinine ratio 5mg/mmol (N < 2.5) What are his prospects for the future, and how should he be managed?

Superficially: Not overweight Not hypertensive Non-diabetic Total cholesterol year cardiovascular risk on NZ CV risk calculator < 5% So – is there a problem? What is your advice?

Yes – he has a big problem – he is genetically programmed to die of cardiovascular disease in his 40’s or 50’s Why? Taking a less superficial look at him…

Being South Asian (on its own) is an important risk factor for type 2 diabetes and cardiovascular disease History of MI or stroke in family members < 55 (men) and <65 (women) is a separate cardiovascular risk factor Abdominal girth 95cm (normal for S.Asians < 90)* Impaired fasting glucose* Prehypertension* Low HDL, elevated triglyceride (atherogenic lipid profile)** Microalbuminuria* - all of the above are separate, quantifiable, and cumulative cardiovascular risk factors in addition he has 6 features* of the metabolic syndrome which confers: x increased risk of cardiovascular events than a simple cumulation of his individial risk factors - substantial (5-10x) higher risk of developing type 2 diabetes

Aims of treatment BMI < 25 Abdominal girth < 90cm BP < 130/80 Fasting glucose < 5.4 LDL cholesterol < 2 Resolution of microalbuminuria How to achieve these goals DASH-Sodium diet High levels of physical activity ACE-inhibitor +/- CCB As much statin as he can tolerate Aspirin Consider metformin

An 83 year old female patients of yours has a long history of systolic hypertension. She had a minor stroke a year ago with good recovery. Recently her BP has been less well-controlled. You see her for a check:- resting seated BP is 180/85, standing 170/82, heart rate 60 bpm. Renal function is normal for age. Her current antihypertensive medications are: metoprolol CR 95mg daily, diltiazem CD 120mg /day, candesartan 32mg daily She is intolerant of thiazides (hyponatraemia – proven on rechallenge) At this age – is more aggressive treatment warranted? If so, how can you improve her blood pressure?

Mean Blood Pressure, Measured while Patients Were Seated, in the Intention-to-Treat Population, According to Study Group Beckett NS et al. N Engl J Med 2008;358:

Treatment Group had: - 30% reduction in in rate of fatal or non-fatal stroke - 39% reduction in rate of death from stroke - 21% reduction in rate of death from any cause - 23% reduction in rate of death from cardiovascular causes - 64% reduction in rate of heart failure

Therapeutic options – Can’t increase metoprolol or diltiazem doses (HR 60) Options (1) Diuretic likely beneficial but can’t tolerate thiazide spironolactone 12.5 – 25mg daily or frusemide 10-20mg BD or TDS …with close monitoring of electrolytes (2) Add amlodipine at 2.5mg daily increasing as tolerated (3) Doxazosin 1mg nocte increasing dose weekly as required

Take Home Messages (1)Hypertension is common in all age groups and is the leading cause of preventable death and disability (2) Most of the excess risk associated with hypertension can be obviated by treating blood pressure to target levels (3)Treatment is complex and time-consuming and patient expectations need to be adjusted accordingly (4) Multi-drug regimens are the norm, and an algorithmic approach to medication adjustment is more likely to be successful than a haphazard one (5) Global cardiovascular risk is an important concept, but don’t get bogged down in the NZ Cardiovascular Risk Guideline which has serious limitations (6)Lifestyle modification is important but (almost) never obviates the need for drugs (7) Any regimen which contains > 2 classes of antihypertensive medication should (almost) always include a diuretic (8) Chlorthalidone is (by far) the most effective thiazide